Does Novelion Therapeutics Inc. (NVLN) Have Any Gas After Today’s Significant Increase?

April 17, 2018 - By Hazel Jackson

The stock of Novelion Therapeutics Inc. (NASDAQ:NVLN) is a huge mover today! The stock increased 9.26% or $0.35 during the last trading session, reaching $4.13. About 65,321 shares traded or 31.54% up from the average. Novelion Therapeutics Inc. (NASDAQ:NVLN) has declined 68.94% since April 17, 2017 and is downtrending. It has underperformed by 80.49% the S&P500.
The move comes after 5 months positive chart setup for the $77.24M company. It was reported on Apr, 17 by Barchart.com. We have $4.34 PT which if reached, will make NASDAQ:NVLN worth $3.86M more.

Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases. The company has market cap of $77.24 million. The Company’s product portfolio includes MYALEPT , a recombinant analogue of human leptin, indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; and lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the brand names of JUXTAPID and LOJUXTA. It currently has negative earnings. The companyÂ’s orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, in late stage development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes.

Novelion Therapeutics Inc. (NASDAQ:NVLN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: